pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

112 catalysts · 25 phase 2 completion · 16 phase 1 completion · 13 phase 2 initiation · 9 patent expiry · 8 phase 1 initiation · 7 phase 0 trial completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 42 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 16 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
TA: pain×TA: infectious-disease×TA: cardiology×TA: ophthalmology×from 2017-05-19×clear all
type
  • phase 2 completion25
  • phase 1 completion16
  • phase 2 initiation13
  • patent expiry9
  • phase 1 initiation8
phase 0 trial completion
7
  • phase 1 2 completion6
  • filing5
  • drug expiry5
  • phase iv trial initiation4
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Apr 20, 2026

    23
    ›Apr 24, 2026patent expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026patent expiry109d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026drug expiry109d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

    Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

    full page →laninamivir →source: globaldata
    ›Apr 24, 2026drug expiry109d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

    Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

    full page →lenvatinib mesylate →source: globaldata
    ›Apr 24, 2026phase 1 results109d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

    Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

    full page →viral-specific T-cells →source: globaldata
    ›Apr 24, 2026phase 1 2 completion109d agoSt. Paul's Hospital — methoxyflurane (Phase I/II Trial Completion)methoxyflurane

    Therapy area: Central Nervous System, Ear Nose Throat Disorders. Indication: Pain, Rhinosinusitis

    full page →methoxyflurane →source: globaldata
    ›Apr 24, 2026phase 2 completion109d agoSwinburne University of Technology — dronabinol (Phase II Trial Completion)dronabinol

    Therapy area: Central Nervous System. Indication: Anxiety Disorders, Insomnia, Pain

    full page →dronabinol →source: globaldata
    ›Apr 24, 2026phase 2 initiation109d agoDasan Pharmaceutical Co Ltd — (acetaminophen + tramadol hydrochloride) (Phase II Trial Initiation)(acetaminophen + tramadol hydrochloride)

    Therapy area: Central Nervous System. Indication: Pain

    full page →(acetaminophen + tramadol hydrochloride) →source: globaldata
    ›Apr 24, 2026phase iv trial initiation109d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →carboxymethylcellulose →source: globaldata
    ›Apr 25, 2026phase 0 trial completion108d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

    full page →EXG-202 →source: globaldata
    ›Apr 25, 2026phase 1 completion108d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

    Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

    full page →influenza (trivalent, split virion) vaccine →source: globaldata
    ›Apr 25, 2026phase 1 completion108d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata
    ›Apr 25, 2026phase 2 completion108d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

    Therapy area: Infectious Disease. Indication: Dental Abscess

    full page →Gengigel →source: globaldata
    ›Apr 25, 2026phase 2 initiation108d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →dostarlimab →source: globaldata
    ›Apr 25, 2026phase iv trial initiation108d agoChristian Medical College Vellore — ketorolac (Phase IV Trial Initiation)ketorolac

    Therapy area: Central Nervous System, Genito Urinary System. Indication: Pain, Renal Colic, Renal Stones/Calculi

    full page →ketorolac →source: globaldata
    ›Apr 26, 2026phase 1 2 completion107d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

    Therapy area: Cardiovascular. Indication: Thrombophlebitis

    full page →ayurvedic medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion107d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

    Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

    full page →unani medicine →source: globaldata
    ›Apr 26, 2026phase 2 completion107d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

    Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

    full page →bupivacaine →source: globaldata
    ›Apr 26, 2026phase 2 initiation107d agoBeijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)oxymetazoline hydrochloride

    Therapy area: Ophthalmology. Indication: Blepharitis, Ptosis

    full page →oxymetazoline hydrochloride →source: globaldata
    ›Apr 26, 2026phase 2 initiation107d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

    Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

    full page →DICLOFENAC SODIUM →source: globaldata
    ›Apr 26, 2026phase 2 results107d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

    full page →artichoke →source: globaldata
    ›Apr 26, 2026phase 3 completion107d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

    Therapy area: Infectious Disease. Indication: Rabies

    full page →rabies vaccine →source: globaldata
    ›Apr 26, 2026phase 3 completion107d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

    Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

    full page →diltiazem →source: globaldata

    Week of Apr 27, 2026

    27
    ›Apr 27, 2026phase 1 initiation106d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

    Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

    full page →pembrolizumab →source: globaldata
    ›Apr 27, 2026constraining patent expiry europe
    ← prev
    page 1 of 3
    next →
    106d ago
    Bill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Europe))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026patent expiry106d agoBill & Melinda Gates Medical Research Institute — SB-692342 (Constraining Patent Expiry (Japan))SB-692342

    Therapy area: Infectious Disease. Indication: Pulmonary Tuberculosis

    full page →SB-692342 →source: globaldata
    ›Apr 27, 2026phase 2 completion106d agoSMBT Ayurved College and Hospital — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

    Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

    full page →ayurvedic medicine →source: globaldata
    ›Apr 27, 2026phase 2 completion106d agoEuropean and Developing Countries Clinical Trials Partnership — (diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine (Phase II Trial Completion)(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine

    Therapy area: Infectious Disease. Indication: Salmonella Infections

    full page →(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B]) vaccine →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoTianjin Lisheng Pharmaceutical Co Ltd — aminophylline (Phase II Trial Initiation)aminophylline

    Therapy area: Cardiovascular, Respiratory. Indication: Asthma, Bronchitis, Emphysema, Pulmonary Edema

    full page →aminophylline →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoMahatma Gandhi Medical College and Hospital — rosuvastatin (Phase II Trial Initiation)rosuvastatin

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Myocardial Infarction

    full page →rosuvastatin →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoYichun Maternal and Child health Care Hospital — sufentanil (Phase II Trial Initiation)sufentanil

    Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

    full page →sufentanil →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoCentral South University Xiangya Hospital 3 — HRS-2129 (Phase II Trial Initiation)HRS-2129

    Therapy area: Central Nervous System. Indication: Pain

    full page →HRS-2129 →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoNational Institute of Neurological Disorders and Stroke — brincidofovir (Phase II Trial Initiation)brincidofovir

    Therapy area: Infectious Disease. Indication: Progressive Multifocal Leukoencephalopathy

    full page →brincidofovir →source: globaldata
    ›Apr 27, 2026phase 2 initiation106d agoAlfred Health Victoria — amiodarone (Phase II Trial Initiation)amiodarone

    Therapy area: Cardiovascular. Indication: Atrial Fibrillation, Congestive Heart Failure (Heart Failure)

    full page →amiodarone →source: globaldata
    ›Apr 27, 2026phase 3 completion106d agoSanofi — meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) (Phase III Trial Completion)meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi)

    Therapy area: Infectious Disease. Indication: Neisseria meningitidis Infections

    full page →meningococcal [serotypes A, C, W-135, Y] vaccine (MenQuadfi) →source: globaldata
    ›Apr 27, 2026phase 3 initiation106d agoZhuhai Qiwei Biotechnology Co Ltd — QA-102 (Phase III Trial Initiation)QA-102

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

    full page →QA-102 →source: globaldata
    ›Apr 27, 2026phase 3 initiation106d agoSiriraj Hospital — tranexamic acid (Phase III Trial Initiation)tranexamic acid

    Therapy area: Cardiovascular, Dermatology. Indication: Melasma (Chlosma), Venous Thromboembolism

    full page →tranexamic acid →source: globaldata
    ›Apr 27, 2026phase iv trial initiation106d agoAll India Institute of Medical Sciences Patna — typhoid Vi polysaccharide vaccine (Phase IV Trial Initiation)typhoid Vi polysaccharide vaccine

    Therapy area: Infectious Disease. Indication: Typhoid Fever

    full page →typhoid Vi polysaccharide vaccine →source: globaldata
    ›Apr 28, 2026constraining patent expiry europe105d agoLupin Ltd — (dolutegravir + lamivudine + tenofovir disoproxil fumarate) (Constraining Patent Expiry (Europe))(dolutegravir + lamivudine + tenofovir disoproxil fumarate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(dolutegravir + lamivudine + tenofovir disoproxil fumarate) →source: globaldata
    ›Apr 28, 2026patent expiry105d agoGSK plc — dolutegravir sodium ODT (Constraining Patent Expiry (Japan))dolutegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →dolutegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry105d agoGSK plc — (abacavir sulfate + dolutegravir sodium+ lamivudine) ODT (Constraining Patent Expiry (Japan))(abacavir sulfate + dolutegravir sodium + lamivudine)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(abacavir sulfate + dolutegravir sodium + lamivudine) →source: globaldata
    ›Apr 28, 2026patent expiry105d agoGSK plc — cabotegravir sodium (Constraining Patent Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026patent expiry105d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Constraining Patent Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026patent expiry105d agoViiV Healthcare UK Ltd — cabotegravir LA (Constraining Patent Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry105d agoGSK plc — cabotegravir sodium (Drug Expiry (US))cabotegravir sodium

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir sodium →source: globaldata
    ›Apr 28, 2026drug expiry105d agoViiV Healthcare UK Ltd — cabotegravir LA (Drug Expiry (US))cabotegravir LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir LA →source: globaldata
    ›Apr 28, 2026drug expiry105d agoViiV Healthcare UK Ltd — cabotegravir + rilpivirine LA (Drug Expiry (US))cabotegravir + rilpivirine LA

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →cabotegravir + rilpivirine LA →source: globaldata
    ›Apr 28, 2026pdufa105d agoMerck & Co Inc — (doravirine + islatravir hydrate) (PDUFA)(doravirine + islatravir hydrate)

    Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

    full page →(doravirine + islatravir hydrate) →source: globaldata
    ›Apr 28, 2026phase 1 completion105d agoInternational Bio Service Co Ltd — Bisoprolol fumarate (Phase I Trial Completion)BISOPROLOL FUMARATE

    Therapy area: Cardiovascular. Indication: Hypertension

    full page →BISOPROLOL FUMARATE →source: globaldata
    ›Apr 28, 2026phase 1 completion105d agoGSK plc — bepirovirsen sodium (Phase I Trial Completion)bepirovirsen sodium

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →bepirovirsen sodium →source: globaldata
    $GSK52.13-1.58%
    $GSK52.13-1.58%
    $GSK52.13-1.58%
    $SNY43.46+1.33%
    $GSK52.13-1.58%
    $GSK52.13-1.58%
    $MRK130.59+1.56%
    $GSK52.13-1.58%